어플

A ruling was issued requiring the Korean government to pay 43.8 billion won in compensation to Mason.

Business / Kim Jisun / 04/12/2024 02:39 AM

(Photo = Provided by Samsung C&T)

[Alpha Biz= Reporter Kim Jisun] In an Investor-State Dispute Settlement (ISDS) filed by U.S. private equity fund operator Mason Capital against the South Korean government, the South Korean government has decided to pay $32.03 million (about KRW 43.8 billion). This is 16% of Mason's damages, the highest recognition rate of damages among government-run ISDS lawsuits.

On the 11th, the Permanent Court of Arbitration (PCA) arbitration court partially cited Mason's claim in an arbitration application filed by Mason against the South Korean government. The panel said, "The South Korean government should pay Mason $32.03 million." The panel also said the government should pay Mason 10.31 million dollars (about 14.1 billion won) in legal costs and 630,000 euros (about 925 million won) in arbitration costs.

The ruling recognized 16% of Mason's damages of about $ 200 million (worth KRW 273.7 billion).

Mason filed an ISDS against the South Korean government in September 2018. Mason claims that the merger between Samsung C&T and Cheil Industries in 2015 was disadvantageous to Samsung C&T shareholders and that the National Pension Service suffered heavy losses in favor of the merger under the pressure of the Park Geun-hye administration. At that time, Mason held a 2.18% stake in Samsung C&T.

 

 

 

AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)

Related articles

[Exclusive] Samsung Electronics to Supply HBM3E 12-High Stacks to NVIDIA
DL E&C Executives Resign En Masse Following Fatal Construction Site Accident
POSCO Future M Terminates KRW 945 Billion ESS Cathode Material Supply Contract, Signs New LFP Partnership with CNGR
Hahn & Company Selects TKG Taekwang as Preferred Bidder for Sale of Semiconductor Parts Maker Solmix
Hyundai Motor Group Bolsters SDV and Autonomous Driving Capabilities with KRW 500.3 Billion Investment in 42dot
comments >

SNS